

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on January 16, 2002, from 10 a.m. to 12:30 p.m.

Location: Holiday Inn, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.

Contact: William Freas, or Sheila D. Langford, Center for Biologics Evaluation and Research (CBER) (HFM-17), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448, 301-827-0314, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 19516. Please call the Information Line for up-to-date information on this meeting.

Agenda: On January 16, 2002, the committee will hear presentations relevant to the site visit report on the review of the research programs of the Laboratory of Bacterial, Parasitic, and Unconventional Agents, and the Laboratory of Molecular Virology, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, CBER.

Procedure: On January 16, 2002, from 10:00 a.m. to 10:45 a.m., and from 11:30 a.m. to 12:30 p.m. the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by January 9, 2002. Oral presentations from the public will be scheduled between approximately 11:30 a.m. to 12:30 p.m. on January 16, 2002. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before January 9, 2002, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On January 16, 2002, from 10:45 a.m. to 11:30 a.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)). The committee will discuss the reports of the review of individual research programs in the Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, Center for Biologics Evaluation and Research.

FDA regrets that it was unable to publish this notice 15 days prior to the

January 16, 2002, Blood Products Advisory Committee meeting. Because the agency believes there is some urgency to bring this issue to public discussion and qualified members of the Blood Products Advisory Committee were available at this time, the Commissioner of Food and Drugs concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: December 26, 2001.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 01-32253 Filed 12-27-01; 5:02 pm]

BILLING CODE 4160-02-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of Inspector General

Program Exclusions: November 2001

AGENCY: Office of Inspector General, HHS.

ACTION: Notice of program exclusions.

During the month of November 2001, the HHS Office of Inspector General imposed exclusions in the cases set forth below. When an exclusion is imposed, no program payment is made to anyone for any items or services (other than an emergency item or service not provided in a hospital emergency room) furnished, ordered or prescribed by an excluded party under the Medicare, Medicaid, and all Federal Health Care programs. In addition, no program payment is made to any business or facility, e.g., a hospital, that submits bills for payment for items or services provided by an excluded party. Program beneficiaries remain free to decide for themselves whether they will continue to use the services of an excluded party even though no program payments will be made for items and services provided by that excluded party. The exclusions have national effect and also apply to all Executive Branch procurement and non-procurement programs and activities.

Subject city, state	Effective date
Program-Related Convictions	
Bilenkin, Elana Old Bridge, NJ	12/20/2001
Birdsong, Stacie Detroit, MI	12/20/2001
Bitz, Jennifer M Jamestown, ND	12/20/2001

Subject city, state	Effective date
Boguslavskiy, Vadim Lavenel, NJ	12/20/2001
Brown, Maurice Chevale Sterling, CO	12/20/2001
Dallakyan, Naira M Pasadena, CA	12/20/2001
Greer, J Randall Memphis, TN	12/20/2001
Gutman, Marci Miami, FL	12/20/2001
Maddox, Yolanda Gail Troy, AL	12/20/2001
McDonald, Anita Fletcher Palestine, TX	12/20/2001
New York Health Plan New York, NY	12/20/2001
Norman, Brigid Riverdale, GA	12/20/2001
Paulin, John Gregory Florence, CO	12/20/2001
Rapp, Donna Lynn Lakewood, CO	12/20/2001
Reyes, Gloria Miami, FL	12/20/2001
Rose, Melba L Miami, FL	12/20/2001
Scarpitta, Janet Newark, NJ	12/20/2001
Stolyar, Yelena Golden, CO	12/20/2001
Taylor, Shirley Jean Pearl, MS	12/20/2001
Urban, Edward J Chargin Fall, OH	12/20/2001

Felony Conviction for Health Care

Brathwaite, Stephen Earl W Valley City, UT	12/20/2001
Burstein, Donald A Warminster, PA	12/20/2001
Casiano, Janet Carle Place, NY	12/20/2001
Fergusson, Olantungie Clar- ence Sherman Oaks, CA	12/20/2001
Oldham, Susan G Lexington, KY	12/20/2001
Runk, Lisa D Wichita, KS	12/20/2001
Seals, Carlos V Los Angeles, CA	12/20/2001

Felony Control Substance Conviction

Davis, Donna K Kidd Somerset, KY	12/20/2001
Gleason, Laura Jane Phoenix, AZ	12/20/2001
Hendrick, Vickie Gallatin, TN	12/20/2001
McMenamin, Deborah J Carbondale, PA	12/20/2001
Sommer, Deborah Jane Dayton, TX	12/20/2001

Patient Abuse/Neglect Convictions

Barsuk, Joseph Jr Churchville, NY	12/20/2001
Boykins, Loretta Penny Baltimore, MD	12/20/2001
Cathey, Deborah Dayton, TX	12/20/2001